An Open-Label, Single Arm, Multi-Center, Phase 2 Study of PD-1 Antibody SHR-1210 in Subjects With Relapsed or Refractory Classic Hodgkin's Lymphoma
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs INCSHR 1210 (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 29 Nov 2017 Status changed from not yet recruiting to recruiting.
- 18 May 2017 New trial record